For novel cancer treatments, effectiveness in clinical practice is not always aligned with clinical efficacy results. As such it is important to understand a treatment’s real-world effectiveness. We examined real-world population-based comparative effectiveness of second-line ipilimumab versus non-ipilimumab treatments (chemotherapy or targeted treatments). | Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma A population-based cohort study in Ontario Canada
